Trattamento del carcinoma gastrico: dati importanti da ASCO GI

[Oncoinfo – Oncology Snapshots: follow us on http://oncoinfo.it] The ASCO GI Cancers Symposium in San Francisco brings important developments in the treatment of GI cancer, both in advanced stages of disease and in the neoadjuvant setting. The most anticipated data are those from the SPOTLIGHT study, which evaluates the treatment with the monoclonal antibody zolbetuximab targeting the novel molecular target claudin 18.2. Filippo Pietrantonio (SS Gastroenterological Medical Oncology - IRCCS National Cancer Institute Foundation, Milan) discusses them.